| Name | Title | Contact Details |
|---|---|---|
Mark Hermes |
Chief Commercial Officer (CCO) | Profile |
Sleep Prescription is a Rancho Santa Margarita, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tobira Therapeutics is a clinical-stage biopharmaceutical company developing cenicriviroc (CVC), an oral potent dual inhibitor of chemokine receptors CCR2 and CCR5. Tobira is initiating a Phase 2 clinical trial of cenicriviroc for the treatment of Nonalcoholic Steatohepatitis (NASH), a leading cause of cirrhosis and liver transplant. The company has also completed a Phase 2b clinical trial of cenicriviroc in 143 HIV-infected subjects, and the compound is positioned for Phase 3 studies as a novel, once daily, fixed-dose cenicriviroc/lamivudine backbone as part of combination HIV therapy. Tobira is backed by a syndicate of leading life science investors including Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners, Novo Ventures and Canaan Partners.
We design and manufacture functional and sustainable applications for human and veterinary immobilization and mobility.
SubjectWell provides risk-free patient recruitment for clinical trials. We engage the 96% of Americans who have never participated in clinical trials and we only charge for those who randomize.